## Aromatase, $17\hat{l}^2$ -hydroxysteroid dehydrogenase and int concentrations in cancerous and normal glandular brea women

European Journal of Cancer & Clinical Oncology 22, 515-525 DOI: 10.1016/0277-5379(86)90121-5

**Citation Report** 

#	Article	IF	CITATIONS
1	Aromatase activity in normal breast and breast tumor tissues: In vivo and in vitro studies. Steroids, 1987, 50, 269-279.	1.8	204
2	Mammary steroidogenesis: Therapeutic implications. International Journal of Radiation Applications and Instrumentation Part B, Nuclear Medicine and Biology, 1987, 14, 369-375.	0.3	4
3	Subcellular concentrations of estrone, estradiol, androstenedione and 17β-hydroxysteroid dehydrogenase (17-β-OH-SDH) activity in malignant and non-malignant human breast tissues. International Journal of Cancer, 1987, 40, 305-308.	5.1	23
4	Progress in understanding breast cancer: Epidemiological and biological interactions. Breast Cancer Research and Treatment, 1988, 11, 91-112.	2.5	42
5	The effects of androgens and cortisol on the in vivo metabolism of oestradiol. The Journal of Steroid Biochemistry, 1988, 30, 489-492.	1.1	2
6	Clinical and endocrine effects of cyproterone acetate in postmenopausal patients with advanced breast cancer. European Journal of Cancer & Clinical Oncology, 1988, 24, 417-421.	0.7	20
7	Mechanisms of Action of Aminoglutethimide as Endocrine Therapy of Breast Cancer. Drugs, 1988, 35, 685-710.	10.9	96
8	Oestrogen uptake and metabolism in vivo. Proceedings of the Royal Society of Edinburgh Section B Biological Sciences, 1989, 95, 185-193.	0.2	8
9	The relevance of local oestrogen metabolism within the breast. Proceedings of the Royal Society of Edinburgh Section B Biological Sciences, 1989, 95, 203-217.	0.2	7
10	Biosynthesis of active oestrogens in the breast. Proceedings of the Royal Society of Edinburgh Section B Biological Sciences, 1989, 95, 195-201.	0.2	5
11	In vivo influence of androgens on the cell kinetics and chromatin pattern of the MXT mouse mammary tumor treated or not by aminogluthetimide. Journal of Cancer Research and Clinical Oncology, 1989, 115, 129-138.	2.5	9
12	in situ oestrone synthesis in normal breast and breast tumour tissues: Effect of treatment with 4-hydroxyandrostenedione. International Journal of Cancer, 1989, 44, 233-237.	5.1	157
13	Endogenous oestrogens and androgens in normal and malignant endometrial and mammary tissues. European Journal of Cancer & Clinical Oncology, 1989, 25, 1953-1959.	0.7	59
14	Inhibitory action of androstenedione on the proliferation and cell cycle kinetics of aromatase-free MXT and MCF-7 mammary tumour cell lines. European Journal of Cancer & Clinical Oncology, 1989, 25, 837-843.	0.7	14
15	A possible mechanism for increased breast cell proliferation by progestins through increased reductive 17l²-hydroxysteroid dehydrogenase activity. International Journal of Cancer, 1990, 45, 174-178.	5.1	48
16	Estrone sulfate stimulates growth of nitrosomethylurea-induced breast carcinomain vivo in the rat. International Journal of Cancer, 1990, 46, 73-78.	5.1	29
17	Progestin induction of 17β-hydroxysteroid dehydrogenase enzyme protein in the t-47D human breast-cancer cell line. International Journal of Cancer, 1990, 46, 897-901.	5.1	48
18	Endocrine treatment for breast cancers: Biological rationale and current progress. Journal of Steroid Biochemistry and Molecular Biology, 1990, 37, 467-480.	2.5	49

#	Article	IF	CITATIONS
19	The significance of steroid metabolism in human cancer. Journal of Steroid Biochemistry and Molecular Biology, 1990, 37, 317-325.	2.5	34
20	Regulation of Estrogen Concentrations in Human Breast Tissues. Annals of the New York Academy of Sciences, 1990, 595, 227-235.	3.8	23
21	Postmenopausal estrogen synthesis and metabolism: Alterations caused by aromatase inhibitors used for the treatment of breast cancer. The Journal of Steroid Biochemistry, 1990, 35, 355-366.	1.1	93
22	Regulation of oestradiol 17β hydroxysteroid dehydrogenase in breast tissues: The role of growth factors. Journal of Steroid Biochemistry and Molecular Biology, 1991, 39, 791-798.	2.5	39
23	Steroid hormones in lymph and blood from women with early breast cancer. European Journal of Cancer & Clinical Oncology, 1991, 27, 42-44.	0.7	1
24	Endogenous steroid hormones and local aromatase activity in the breast. Journal of Steroid Biochemistry and Molecular Biology, 1991, 39, 799-804.	2.5	51
25	EGF in breast cyst fluid: Relationships with intracystic androgens, estradiol and progesterone. International Journal of Cancer, 1991, 47, 523-526.	5.1	21
26	Concentrations of oestrone and 4-hydroxyandrostenedione in malignant and normal breast tissues. International Journal of Cancer, 1991, 49, 562-565.	5.1	56
27	Aromatase Inhibitors in Malignant Diseases of Aging. Drugs and Aging, 1992, 2, 530-545.	2.7	14
28	Identification of albumin in breast tumor cytosol as a factor involved in the stimulation of estradiol 17β-hydroxysteroid dehydrogenase (reductive) activity. Molecular and Cellular Endocrinology, 1992, 83, 85-92.	3.2	12
29	Synergistic interaction of growth factors and albumin in regulating estradiol synthesis in breast cancer cells. Molecular and Cellular Endocrinology, 1992, 85, 165-173.	3.2	24
30	Oestradiol synthesis from oestrone in malignant breast epithelial cells: Studies on a high affinity, 80 kDa form of oestradiol dehydrogenase. Journal of Steroid Biochemistry and Molecular Biology, 1992, 42, 891-900.	2.5	8
31	Contribution of aromatase to the deoxyribonucleic acid synthesis of MCF-7 human breast cancer cells and its suppression by aromatase inhibitors. Journal of Steroid Biochemistry and Molecular Biology, 1992, 42, 267-277.	2.5	40
32	Aromatase activity and estradiol in human breast cancer: its relationship to estradiol and epidermal growth factor receptors and to tumor-node-metastasis staging Journal of Clinical Oncology, 1992, 10, 438-446.	1.6	58
33	Immunological analysis of 17β-hydroxysteroid dehydrogenase in benign and malignant human breast tissue. International Journal of Cancer, 1992, 50, 386-390.	5.1	115
34	Action of danazol on the conversion of estrone sulfate to estradiol and on the sulfatase activity in the MCF-7, T-47D and MDA-MB-231 human mammary cancer cells. Journal of Steroid Biochemistry and Molecular Biology, 1993, 46, 17-23.	2.5	29
35	The anti-estrogen tamoxifen blocks the stimulatory effects of interleukin-6 on 17β-hydroxysteroid dehydrogenase activity in MCF-7 cells. Journal of Steroid Biochemistry and Molecular Biology, 1993, 46, 605-611.	2,5	16
36	Tobacco alkaloid derivatives as inhibitors of breast cancer aromatase. Cancer Letters, 1993, 75, 175-182.	7.2	34

#	Article	IF	CITATIONS
37	Local aromatase activity in human breast tissues. Journal of Steroid Biochemistry and Molecular Biology, 1993, 44, 577-582.	2.5	19
38	Prognostic significance of aromatase and estrone sulfatase enzymes in human breast cancer. Journal of Steroid Biochemistry and Molecular Biology, 1993, 44, 583-587.	2.5	32
39	Interactive effects of interleukin-6, 17β-estradiol and progesterone on growth and 17β-hydroxysteroid dehydrogenase activity in human breast carcinoma cells. Journal of Steroid Biochemistry and Molecular Biology, 1993, 46, 11-15.	2.5	23
40	Control of aromatase activity in breast cancer cells: The role of cytokines and growth factors. Journal of Steroid Biochemistry and Molecular Biology, 1993, 44, 589-596.	2.5	110
41	Steroid Biosynthetic Enzymes: 17 β Hydroxysteroid Dehydrogenase. Annals of Medicine, 1993, 25, 91-97.	3.8	21
42	Androgen receptor-mediated stimulation of 17 beta-hydroxysteroid dehydrogenase activity by dihydrotestosterone and medroxyprogesterone acetate in ZR-75-1 human breast cancer cells Endocrinology, 1993, 132, 179-185.	2.8	56
43	The role of aromatase in breast tumors. Breast Cancer Research and Treatment, 1994, 30, 7-17.	2.5	53
44	Aromatase inhibitors ? mechanisms for non-steroidal inhibitors. Breast Cancer Research and Treatment, 1994, 30, 43-55.	2.5	71
45	Sex hormone levels in postmenopausal women with advanced metastatic breast cancer treated with CGS 169 49A. European Journal of Cancer, 1994, 30, 1254-1258.	2.8	13
46	Inhibition of steroid sulphatase activity by steroidal methylthiophosphonates: Potential therapeutic agents in breast cancer. Journal of Steroid Biochemistry and Molecular Biology, 1994, 48, 523-527.	2.5	13
47	Stimulation of aromatase activity in breast fibroblasts by tumor necrosis factor. Molecular and Cellular Endocrinology, 1994, 106, 17-21.	3.2	104
48	Interleukin-3: A putative protective factor against breast cancer which is secreted by male but not female breast fibroblasts. International Journal of Cancer, 1995, 61, 416-419.	5.1	8
49	Transformation of estrone and estradiol in hormone-dependent and hormone-independent human breast cancer cells. Breast Cancer Research and Treatment, 1995, 34, 139-146.	2.5	46
50	Inhibitory effect of a steroidal antiestrogen (EM-170) on estrone-stimulated growth of 7,12-dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat. Breast Cancer Research and Treatment, 1995, 33, 237-244.	2.5	12
51	Dehydroepiandrosterone concentration in breast cancer tissue is related to its plasma gradient across the mammary gland. Breast Cancer Research and Treatment, 1995, 33, 171-177.	2.5	12
52	Regulation of Oestrogen Action: Role of 17β-hydroxysteroid Dehydrogenases. Annals of Medicine, 1995, 27, 675-682.	3.8	26
53	Testosterone, dihydrotestosterone and oestradiol levels in postmenopausal breast cancer tissues. Journal of Steroid Biochemistry and Molecular Biology, 1995, 52, 541-546.	2.5	98
54	The role and proposed mechanism by which oestradiol 17β-hydroxysteroid dehydrogenase regulates breast tumour oestrogen concentrations. Journal of Steroid Biochemistry and Molecular Biology, 1995, 55, 565-572.	2.5	40

#	Article	IF	CITATIONS
55	Optimization of a classical aromatase activity assay and application in normal, adenomatous and malignant breast parenchyma. Journal of Steroid Biochemistry and Molecular Biology, 1996, 59, 305-313.	2.5	9
56	Intratumour amount of sex steroids in elderly breast cancer patients. An approach to the biological characterization of mammary tumours in the elderly. Journal of Steroid Biochemistry and Molecular Biology, 1996, 58, 557-561.	2.5	7
57	Heteroatom-substituted analogues of the active-site directed inhibitor estra-1,3,5(10)-trien-17-one-3-sulphamate inhibit estrone sulphatase by a different mechanism. Journal of Steroid Biochemistry and Molecular Biology, 1996, 57, 79-88.	2.5	76
58	Estrogen Content and Metabolism in Human Breast Tumor Tissues and Cells. Annals of the New York Academy of Sciences, 1996, 784, 314-324.	3.8	22
59	Steroid hormones and cancer: (I) Basic biology and endocrinology. European Journal of Surgical Oncology, 1996, 22, 627-633.	1.0	3
60	Effect of nomegestrol acetate on estrone-sulfatase and 17β-hydroxysteroid dehydrogenase activities in human breast cancer cells. Journal of Steroid Biochemistry and Molecular Biology, 1996, 58, 525-531.	2.5	47
61	Human 17 <i>β</i> -hydroxysteroid dehydrogenase type 1 and type 2 isoenzymes have opposite activities in cultured cells and characteristic cell- and tissue-specific expression. Biochemical Journal, 1996, 314, 839-845.	3.7	181
62	Aromatase in breast cancer tissue ? localization and relationship with reproductive status of patients. Journal of Cancer Research and Clinical Oncology, 1996, 122, 495-498.	2.5	26
63	Characterization of estrogen-dependent growth of cultured MCF-7 human breast-cancer cells expressing 17β-hydroxysteroid dehydrogenase type 1. , 1996, 68, 600-604.		36
64	Synthesis and evaluation of estradiol derivatives with 16α-(bromoalkylamide), 16α-(bromoalkyl) or 16α-(bromoalkynyl) side chain as inhibitors of 17β-hydroxysteroid dehydrogenase type 1 without estrogenic activity. Bioorganic and Medicinal Chemistry, 1996, 4, 1617-1628.	3.0	23
65	17Â-Hydroxysteroid dehydrogenase: inhibitors and inhibitor design. Endocrine-Related Cancer, 1996, 3, 41-56.	3.1	71
66	Presence of alternatively spliced transcripts of aromatase gene in human breast cancer Journal of Clinical Endocrinology and Metabolism, 1996, 81, 2344-2349.	3.6	94
67	Effect of Dehydroepiandrosterone on Bone Mass, Serum Lipids, and Dimethylbenz(a)anthracene-Induced Mammary Carcinoma in the Rat*. Endocrinology, 1997, 138, 3387-3394.	2.8	29
68	Characterization of Structural and Functional Properties of Human 17β-Hydroxysteroid Dehydrogenase Type 1 Using Recombinant Enzymes and Site-Directed Mutagenesis. Molecular Endocrinology, 1997, 11, 77-86.	3.7	53
69	Control of estrone sulfatase activity in human breast cancer cells: Effect of tibolone and its metabolites. Gynecological Endocrinology, 1997, 11, 69-75.	1.7	9
70	Breast Cancer and the Role of Cytokines in Regulating Estrogen Synthesis: An Emerging Hypothesis. Endocrine Reviews, 1997, 18, 701-715.	20.1	117
71	Aberrant expression of aromatase in breast cancer tissues. Journal of Steroid Biochemistry and Molecular Biology, 1997, 61, 175-184.	2.5	124
72	Aromatase in the normal breast and breast cancer. Journal of Steroid Biochemistry and Molecular Biology, 1997, 61, 281-286.	2.5	86

#	Article	IF	CITATIONS
73	Steroid hormones and cancer: (III) Observations from human subjects. European Journal of Surgical Oncology, 1997, 23, 163-177.	1.0	27
74	Estrone sulfonates as inhibitors of estrone sulfatase. Steroids, 1997, 62, 346-350.	1.8	37
75	Concentrations of estrone, estradiol and their sulfates, and evaluation of sulfatase and aromatase activities in patients with breast fibroadenoma. International Journal of Cancer, 1997, 70, 639-643.	5.1	94
76	Biochemical control of breast aromatase. Breast Cancer Research and Treatment, 1998, 49, S9-S14.	2.5	5
77	Clinical importance of intratumoral aromatase. Breast Cancer Research and Treatment, 1998, 49, S27-S32.	2.5	29
78	Short-term primary culture of epithelial cells derived from human breast tumours. British Journal of Cancer, 1998, 78, 1421-1429.	6.4	88
79	A 6β-(thiaheptanamide) derivative of estradiol as inhibitor of 17β-hydroxysteroid dehydrogenase type 1. Journal of Steroid Biochemistry and Molecular Biology, 1998, 64, 83-90.	2.5	36
80	Progestins and breast cancer. Journal of Steroid Biochemistry and Molecular Biology, 1998, 65, 225-235.	2.5	55
81	Regulation of sex steroid formation by interleukin-4 and interleukin-6 in breast cancer cells. Journal of Steroid Biochemistry and Molecular Biology, 1998, 65, 151-162.	2.5	32
82	Activity and gene expression of 17Î2-hydroxysteroid dehydrogenase type I in primary cultures of epithelial and stromal cells derived from normal and tumourous human breast tissue: the role of IL-8. Journal of Steroid Biochemistry and Molecular Biology, 1998, 67, 267-274.	2.5	57
83	Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis, 1998, 19, 1-27.	2.8	793
84	Plasma Sex Steroid Hormone Levels and Risk of Breast Cancer in Postmenopausal Women. Journal of the National Cancer Institute, 1998, 90, 1292-1299.	6.3	610
85	Unusual Charge Stabilization of NADP+ in 17β-Hydroxysteroid Dehydrogenase. Journal of Biological Chemistry, 1998, 273, 8145-8152.	3.4	77
86	Alteration of oestradiol metabolism in myc oncogene-transfected mouse mammary epithelial cells. British Journal of Cancer, 1998, 77, 1549-1554.	6.4	5
87	Regulation of Estrogen Action: Role of 17β-Hydroxysteroid Dehydrogenases. Vitamins and Hormones, 1998, , 353-398.	1.7	37
88	Biological effects of progestins in breast cancer. Gynecological Endocrinology, 1999, 13, 11-19.	1.7	6
89	Aromatase within the breast Endocrine-Related Cancer, 1999, 6, 157-164.	3.1	43
90	17βâ€hydroxysteroid dehydrogenases in normal human mammary epithelial cells and breast tissue. Breast Cancer Research and Treatment, 1999, 57, 175-182.	2.5	58

	Сітатіс	on Report	
#	Article	IF	Citations
91	Significance of steroid sulfatase expression in human breast cancer. Breast Cancer, 1999, 6, 298-300.	2.9	19
92	The SEEM: Selective Estrogen Enzyme Modulators in breast cancer. Gynecological Endocrinology, 1999, 13, 1-8.	1.7	11
93	Effect of Medrogestone on 17β-hydroxysteroid dehydrogenase activity in the hormone-dependent MCF-7 and T-47D human breast cancer cell lines. Journal of Steroid Biochemistry and Molecular Biology, 1999, 68, 51-56.	2.5	18
94	Estrone sulfatase versus estrone sulfotransferase in human breast cancer: potential clinical applications. Journal of Steroid Biochemistry and Molecular Biology, 1999, 69, 287-292.	2.5	61
95	Control of sulfatase and sulfotransferase activities by medrogestone in the hormone-dependent MCF-7 and T-47D human breast cancer cell lines. Journal of Steroid Biochemistry and Molecular Biology, 1999, 70, 39-45.	2.5	41
96	Human Estrogenic 17β-Hydroxysteroid Dehydrogenase: Predominance of Estrone Reduction and Its Induction by NADPH. Biochemical and Biophysical Research Communications, 1999, 259, 489-493.	2.1	47
97	Altering the Estrogenic Milieu of Breast Cancer with a Focus on the New Aromatase Inhibitors. Pharmacotherapy, 2000, 20, 280-291.	2.6	2
98	Tibolone $\hat{a}$ €" an alternative to estrogen substitution. Der Gynakologe, 2000, 33, 408-415.	1.0	0
99	Radiolabeled estradiol derivatives to predict response to hormonal treatment in breast cancer: a review. European Journal of Nuclear Medicine and Molecular Imaging, 2000, 27, 1421-1433.	2.1	37
100	Sex Steroid Hormones in Serum and Tissue of Benign and Malignant Breast Tumor Patients. Disease Markers, 2000, 16, 151-157.	1.3	35
101	Intracrinology: role of the family of 17 beta-hydroxysteroid dehydrogenases in human physiology and disease. Journal of Molecular Endocrinology, 2000, 25, 1-16.	2.5	264
102	A nuclear receptor system constituted by RAR and RXR induces aromatase activity in MCF-7 human breast cancer cells. Molecular and Cellular Endocrinology, 2000, 166, 137-145.	3.2	25
103	A novel HPLC-RIA method for the simultaneous detection of estrone, estradiol and estrone sulphate levels in breast cancer tissue. Journal of Steroid Biochemistry and Molecular Biology, 2000, 72, 259-264.	2.5	83
104	Comparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal, and in cancerous, human breast tissues. Journal of Steroid Biochemistry and Molecular Biology, 2000, 72, 23-27.	2.5	256
105	Elevated steroid sulfatase expression in breast cancers. Journal of Steroid Biochemistry and Molecular Biology, 2000, 73, 141-145.	2.5	102
106	Crucial role of cytokines in sex steroid formation in normal and tumoral tissues. Molecular and Cellular Endocrinology, 2001, 171, 25-40.	3.2	41
107	Structure and function of 17β-hydroxysteroid dehydrogenase type 1 and type 2. Molecular and Cellular Endocrinology, 2001, 171, 71-76.	3.2	54
108	The selective estrogen enzyme modulator (SEEM) in breast cancer. Journal of Steroid Biochemistry and Molecular Biology, 2001, 76, 95-104.	2.5	50

ARTICLE IF CITATIONS Paradoxical effect of estradiol: it can block its own bioformation in human breast cancer cells. 109 2.5 31 Journal of Steroid Biochemistry and Molecular Biology, 2001, 78, 21-24. Aromatase and COX-2 expression in human breast cancers. Journal of Steroid Biochemistry and 2.5 Molecular Biology, 2001, 79, 41-47. Stepwise estrogen suppression manipulating the estrostat. Journal of Steroid Biochemistry and 111 2.519 Molecular Biology, 2001, 79, 127-132. Analysis of transcriptional regulation of human breast aromatase by in vitro and in vivo studies. Journal of Steroid Biochemistry and Molecular Biology, 2001, 79, 151-156. Evaluation of 7-Hydroxy-Flavones as Inhibitors of Oestrone and Oestradiol Biosynthesis. Journal of 113 0.5 1 Enzyme Inhibition and Medicinal Chemistry, 2001, 16, 417-424. Aromatase regulation and breast cancer. Clinical Endocrinology, 2001, 54, 563-571. 2.4 Involvement of up-regulation of 17?-hydroxysteroid dehydrogenase type 1 in maintenance of 115 intratumoral high estradiol levels in postmenopausal breast cancers. International Journal of 5.1 132 Cancer, 2001, 94, 685-689. Codon 89 polymorphism in the human 5 α -reductase gene in primary breast cancer. British Journal of 6.4 16 Cancer, 2001, 84, 760-767. Constitutive Expression of the Steroid Sulfatase Gene Supports the Growth of MCF-7 Human Breast 117 2.8 34 Cancer Cells in Vitroand in Vivo\*. Endocrinology, 2001, 142, 1497-1505. Inhibitors of steroidogenesis as agents for the treatment of hormone-dependent cancers. Expert 118 Opinion on Therapeutic Patents, 2001, 11, 789-824. Estrone 3-Sulfate Mimics, Inhibitors of Estrone Sulfatase Activity:Â Homology Model Construction and 119 2.5 23 Docking Studiesâ€. Biochemistry, 2002, 41, 14801-14814. Aromatase Inhibitors and Inactivators for Breast Cancer Therapy. Drugs and Aging, 2002, 19, 277-298. Chemoprevention of Breast Cancer. Drugs and Aging, 2002, 19, 43-78. 121 2.7 6 Roles of androgens in the development, growth, and carcinogenesis of the mammary gland. Journal of 2.5 142 Steroid Biochemistry and Molecular Biology, 2002, 80, 175-189. 17Î<sup>2</sup>-Hydroxysteroid dehydrogenases and cancers. Journal of Steroid Biochemistry and Molecular 123 2.529 Biology, 2002, 83, 119-122. Hormone receptors and proliferation in breast carcinomas of equivalent histologic grades in pre- and 124 5.1 postmenopausal women. International Journal of Cancer, 2002, 98, 118-127. Carcinogenic activity in estrone and its derivatives: a theoretical study. Computational and 125 1.510 Theoretical Chemistry, 2003, 624, 29-36. Norelgestromin as selective estrogen enzyme modulator in human breast cancer cell lines. Journal of Steroid Biochemistry and Molecular Biology, 2003, 84, 193-198.

#	Article	IF	CITATIONS
127	Role of steroid sulfatase in local formation of estrogen in post-menopausal breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology, 2003, 86, 455-460.	2.5	54
128	Breast cancer tissue estrogens and their manipulation with aromatase inhibitors and inactivators. Journal of Steroid Biochemistry and Molecular Biology, 2003, 86, 245-253.	2.5	122
129	Hormonal effects of aromatase inhibitors: focus on premenopausal effects and interaction with tamoxifen. Journal of Steroid Biochemistry and Molecular Biology, 2003, 86, 255-263.	2.5	73
130	Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis. Journal of Steroid Biochemistry and Molecular Biology, 2003, 86, 477-486.	2.5	227
131	Aromatase inhibitors in breast cancer Endocrine-Related Cancer, 2004, 11, 179-189.	3.1	76
132	Estrogen mediates Aurora-A overexpression, centrosome amplification, chromosomal instability, and breast cancer in female ACI rats. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 18123-18128.	7.1	127
133	17β-Hydroxysteroid Dehydrogenase Type 1 Is an Independent Prognostic Marker in Breast Cancer. Cancer Research, 2004, 64, 7604-7609.	0.9	111
134	Correlates of obesity in postmenopausal women with breast cancer: comparison of genetic, demographic, disease-related, life history and dietary factors. International Journal of Obesity, 2004, 28, 49-56.	3.4	40
135	The selective estrogen enzyme modulators in breast cancer: a review. Biochimica Et Biophysica Acta: Reviews on Cancer, 2004, 1654, 123-143.	7.4	95
136	Local biosynthesis and metabolism of oestrogens in the human breast. Maturitas, 2004, 49, 25-33.	2.4	28
137	17β-Hydroxysteroid dehydrogenases—their role in pathophysiology. Molecular and Cellular Endocrinology, 2004, 215, 83-88.	3.2	63
138	Effects of oestradiol and tamoxifen on VEGF, soluble VEGFR-1, and VEGFR-2 in breast cancer and endothelial cells. British Journal of Cancer, 2005, 93, 1005-1010.	6.4	77
139	Endogenous Sex Hormone Levels and Mammographic Density among Postmenopausal Women. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 2641-2647.	2.5	115
140	Increased extracellular local levels of estradiol in normal breast in vivo during the luteal phase of the menstrual cycle. Journal of Endocrinology, 2005, 187, 103-108.	2.6	27
141	Serum Lipids, Lipid-Lowering Drugs, and the Risk of Breast Cancer. Archives of Internal Medicine, 2005, 165, 2264.	3.8	108
142	Aromatase inhibitors in the treatment of early and advanced breast cancer. Acta Oncológica, 2005, 44, 23-31.	1.8	27
143	Enzymes as modulators in malignant transformation. Journal of Steroid Biochemistry and Molecular Biology, 2005, 93, 277-283.	2.5	63
144	Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer. Journal of Steroid Biochemistry and Molecular Biology, 2005, 93, 221-236.	2.5	179

#	ARTICLE	IF	CITATIONS
145	Endocrine effects of aromatase inhibitors and inactivators in vivo: Review of data and method limitations. Journal of Steroid Biochemistry and Molecular Biology, 2005, 95, 75-81.	2.5	61
146	Treatment with high-dose estrogen (diethylstilbestrol) significantly decreases plasma estrogen and androgen levels but does not influence in vivo aromatization in postmenopausal breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology, 2005, 96, 415-422.	2.5	16
147	Estradiolâ^'Adenosine Hybrid Compounds Designed to Inhibit Type 1 17β-Hydroxysteroid Dehydrogenase. Journal of Medicinal Chemistry, 2005, 48, 8134-8147.	6.4	48
148	Control of cell proliferation by steroids: The role of 17HSDs. Molecular and Cellular Endocrinology, 2006, 248, 141-148.	3.2	49
149	What do we know about the mechanisms of aromatase inhibitor resistance?. Journal of Steroid Biochemistry and Molecular Biology, 2006, 102, 232-240.	2.5	65
150	Estrogen controls PKCε-dependent mechanical hyperalgesia through direct action on nociceptive neurons. European Journal of Neuroscience, 2006, 24, 527-534.	2.6	100
151	Aromatase Inhibitors: Structural Features and Biochemical Characterization. Annals of the New York Academy of Sciences, 2006, 1089, 237-251.	3.8	60
152	Grape Seed Extract Is an Aromatase Inhibitor and a Suppressor of Aromatase Expression. Cancer Research, 2006, 66, 5960-5967.	0.9	74
153	Genistein stimulates growth of human breast cancer cells in a novel, postmenopausal animal model, with low plasma estradiol concentrations. Carcinogenesis, 2006, 27, 1292-1299.	2.8	104
154	Endogenous Hormone Levels, Mammographic Density, and Subsequent Risk of Breast Cancer in Postmenopausal Women. Journal of the National Cancer Institute, 2007, 99, 1178-1187.	6.3	207
155	Endogenous estrogen, testosterone and progesterone levels in relation to breast cancer risk. Journal of Steroid Biochemistry and Molecular Biology, 2007, 106, 24-30.	2.5	104
156	New experimental models for aromatase inhibitor resistance. Journal of Steroid Biochemistry and Molecular Biology, 2007, 106, 8-15.	2.5	31
157	Progestins and breast cancer. Gynecological Endocrinology, 2007, 23, 32-41.	1.7	34
158	Targeted functional imaging in breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 346-353.	6.4	9
159	Inhibition of steroid sulfatase activity and cell proliferation in ZR-75-1 and BT-474 human breast cancer cells by KW-2581 in vitro and in vivo. Breast Cancer Research and Treatment, 2007, 104, 211-219.	2.5	23
160	A new polymorphism in the coding region of exon four in HSD17B2 in relation to risk of sporadic and hereditary breast cancer. Breast Cancer Research and Treatment, 2007, 106, 57-64.	2.5	12
161	A novel steroidal selective steroid sulfatase inhibitor KW-2581 inhibits sulfated-estrogen dependent growth of breast cancer cells in vitro and in animal models. Breast Cancer Research and Treatment, 2007, 106, 215-227.	2.5	30
162	The discovery and mechanism of action of letrozole. Breast Cancer Research and Treatment, 2007, 105, 7-17.	2.5	174

#	Article	IF	Citations
163	Expression of aromatase and estrogen sulfotransferase in preinvasive and invasive breast cancer. Journal of Cancer Research and Clinical Oncology, 2007, 134, 67-73.	2.5	20
164	Development of a high sensitivity, nested Q-PCR assay for mouse and human aromatase. Breast Cancer Research and Treatment, 2008, 111, 343-351.	2.5	8
165	A significant proportion of elderly patients develop hormone-dependant "luminal-B―tumours associated with aggressive characteristics. Critical Reviews in Oncology/Hematology, 2008, 67, 80-92.	4.4	51
166	In vivo measurement of tumor estradiol and Vascular Endothelial Growth Factor in breast cancer patients. BMC Cancer, 2008, 8, 73.	2.6	44
167	Aromatase inhibitors: Assessment of biochemical efficacy measured by total body aromatase inhibition and tissue estrogen suppression. Journal of Steroid Biochemistry and Molecular Biology, 2008, 108, 196-202.	2.5	20
168	Measurement of Sex Steroid Hormones in Breast Adipocytes: Methods and Implications. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 1891-1895.	2.5	22
169	Clinical Importance of Estrogen Receptor-β Evaluation in Breast Cancer Patients Treated With Adjuvant Tamoxifen Therapy. Journal of Clinical Oncology, 2008, 26, 3727-3734.	1.6	210
170	Phytochemicals for breast cancer prevention by targeting aromatase. Frontiers in Bioscience - Landmark, 2009, Volume, 3846.	3.0	27
171	Design, chemical synthesis, and in vitro biological evaluation of simplified estradiol–adenosine hybrids as inhibitors of 17β-hydroxysteroid dehydrogenase type 1. Canadian Journal of Chemistry, 2009, 87, 1180-1199.	1.1	13
172	Nomegestrol acetate is an anti-aromatase agent in human MCF-7aro breast cancer cells. Hormone Molecular Biology and Clinical Investigation, 2010, 3, 417-24.	0.7	3
173	Aromatase inhibition in male breast cancer patients: biological and clinical implications. Annals of Oncology, 2010, 21, 1243-1245.	1.2	76
174	Steroid sulfatase: A pivotal player in estrogen synthesis and metabolism. Molecular and Cellular Endocrinology, 2011, 340, 154-160.	3.2	55
175	Recent data on intratumor estrogens in breast cancer. Steroids, 2011, 76, 786-791.	1.8	28
176	Estrogen-induced reactive oxygen species-mediated signalings contribute to breast cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2011, 1815, 115-133.	7.4	102
177	Estrogens in the breast tissue: a systematic review. Cancer Causes and Control, 2011, 22, 529-540.	1.8	65
178	Exploring Breast Cancer Estrogen Disposition: The Basis for Endocrine Manipulation. Clinical Cancer Research, 2011, 17, 4948-4958.	7.0	58
179	Mammographic Breast Density and Subsequent Risk of Breast Cancer in Postmenopausal Women According to Tumor Characteristics. Journal of the National Cancer Institute, 2011, 103, 1179-1189.	6.3	192
180	The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum. Annals of Oncology, 2011, 22, 503-514.	1.2	56

#	Article	IF	CITATIONS
181	Androgen receptors and serum testosterone levels identify different subsets of postmenopausal breast cancers. BMC Cancer, 2012, 12, 599.	2.6	16
182	Estrogen Receptor Alpha Interacts with Mitochondrial Protein HADHB and Affects Beta-Oxidation Activity. Molecular and Cellular Proteomics, 2012, 11, M111.011056-1-M111.011056-12.	3.8	50
183	Sex steroid hormone levels in breast adipose tissue and serum in postmenopausal women. Breast Cancer Research and Treatment, 2012, 131, 287-294.	2.5	32
184	Progesterone – promoter or inhibitor of breast cancer. Climacteric, 2013, 16, 54-68.	2.4	43
185	Breast Adipose Tissue Estrogen Metabolism in Postmenopausal Women With or Without Breast Cancer. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E2661-E2667.	3.6	33
186	The unique transcriptional response produced by concurrent estrogen and progesterone treatment in breast cancer cells results in upregulation of growth factor pathways and switching from a Luminal A to a Basal-like subtype. BMC Cancer, 2015, 15, 791.	2.6	29
187	Breast cancer treatment and sulfotransferase. Expert Opinion on Therapeutic Targets, 2015, 19, 821-834.	3.4	8
188	Relationships of sex steroid hormone levels in benign and cancerous breast tissue and blood: A critical appraisal of current science. Steroids, 2015, 99, 91-102.	1.8	37
189	The serum estradiol concentration is the main determinant of the estradiol concentration in normal breast tissue. Maturitas, 2015, 81, 42-45.	2.4	17
190	Dense breast tissue in postmenopausal women is associated with a pro-inflammatory microenvironment <i>in vivo</i> . Oncolmmunology, 2016, 5, e1229723.	4.6	18
191	Evaluation of Local CYP17A1 and CYP19A1 Expression Levels as Prognostic Factors in Postmenopausal Invasive Ductal Breast Cancer Cases. Biochemical Genetics, 2016, 54, 784-802.	1.7	10
192	SLCO1B1 polymorphisms and plasma estrone conjugates in postmenopausal women with ER+Âbreast cancer: genome-wide association studies of the estrone pathway. Breast Cancer Research and Treatment, 2017, 164, 189-199.	2.5	17
193	Clinical implications of estrone sulfate measurement in laboratory medicine. Critical Reviews in Clinical Laboratory Sciences, 2017, 54, 73-86.	6.1	11
194	Improved detectability of sex steroids from frozen sections of breast cancer tissue using GC-triple quadrupole-MS. Journal of Steroid Biochemistry and Molecular Biology, 2018, 178, 185-192.	2.5	14
195	The Emerging Roles of Steroid Hormone Receptors in Ductal Carcinoma in Situ (DCIS) of the Breast. Journal of Mammary Gland Biology and Neoplasia, 2018, 23, 237-248.	2.7	10
196	Breast Hormone Concentrations in Random Fine-Needle Aspirates of Healthy Women Associate with Cytological Atypia and Gene Methylation. Cancer Prevention Research, 2018, 11, 557-568.	1.5	3
197	Low-dose environmental endocrine disruptors, increase aromatase activity, estradiol biosynthesis and cell proliferation in human breast cells. Molecular and Cellular Endocrinology, 2019, 486, 55-64.	3.2	58
198	Pre-diagnostic sex hormone levels and survival among breast cancer patients. Breast Cancer Research and Treatment, 2019, 174, 749-758.	2.5	15

#	Article	IF	CITATIONS
199	Measurement of Breast Tissue Estrogens by Liquid Chromatography-tandem Mass Spectrometry. Biomedical Chemistry Research and Methods, 2021, 4, e00147.	0.4	0
201	Estrogen Sulfotransferase in Breast Cancer. , 2005, , 135-156.		2
202	The Selective Estrogen Enzyme Modulators (SEEM) in Breast Cancer. , 2002, , 187-249.		1
203	Androgen excess in breast cancer development: implications for prevention and treatment. Endocrine-Related Cancer, 2019, 26, R81-R94.	3.1	42
204	Influence of age on radiomic features in 18F-FDG PET in normal breast tissue and in breast cancer tumors. Oncotarget, 2018, 9, 30855-30868.	1.8	11
205	Regulation of Aromatase in Normal and Malignant Breast Tissues: The Role of the Immune System. , 2001, , 277-284.		0
206	Mutational Analysis of 17β-hydroxysteroid dehydrogenase type 2 gene in Breast Cancers. Journal of Breast Cancer, 2006, 9, 14.	1.9	0
207	Estrogen-Induced Breast Oncogenesis: Modulation by an Aurora Kinase Inhibitor. Advances in Experimental Medicine and Biology, 2008, 617, 213-220.	1.6	0
208	The Enzymatic Systems in the Formation and Transformation of Estrogens in Normal and Cancerous Human Breast. , 2008, , 11-48.		1
209	Aromatase Inhibitors. , 2009, , 235-263.		0
210	Intra-Mammary Steroid Transformation: Implications for Tumorigenesis and Natural Progression. , 1989, , 185-199.		0
211	Vermeulen, Alex. , 1995, , 593-594.		0
212	Expression and Regulation of 17ß-Hydroxysteroid Dehydrogenase Type 1 in Steroidogenic Cells and Estrogen Target Tissues. , 1996, , 156-166.		0
216	Endocrine, paracrine and intracrine mechanisms of growth regulation in normal and malignant breast epithelium. , 2020, , 44-53.		0
217	Clinical studies with anastrozole. , 2008, , 101-125.		0
219	DHEA, The Precursor of Androgens and Estrogens in Peripheral Tissues in the Human: Intracrinology. , 0, , .		0
220	Deciphering the Conundrum of Estrogen-driven Breast Cancer: Aurora Kinase Deregulation. , 2008, , 49-62.		0
221	Plasma Aromatase Activity Index, Gonadotropins and Estrone Are Associated with Frailty Syndrome in Post-Menopausal Women with Breast Cancer. Current Oncology, 2022, 29, 1744-1760.	2.2	1

#	Article	IF	CITATIONS
222	Effect of estradiol as a continuous variable on breast cancer survival by menopausal status: a cohort study in China. Breast Cancer Research and Treatment, 2022, 194, 103-111.	2.5	1